Skip to main content
SpringerLink
Log in

Population Pharmacokinetics and Pharmacodynamics: An Underutilized Resource

  • Published:
Drug information journal : DIJ / Drug Information Association Aims and scope Submit manuscript

Abstract

A meeting was convened in Canberra, Australia, at the request of the Australian Drug Evaluation Committee (ADEC), on December 3–4, 1997 to discuss the role of population pharmacokinetics and pharmacodynamics in drug evaluation and development. The ADEC was particularly concerned about registration of drugs in the pediatric age group. The population approach could be used more often than is currently the case in pharmaco-kinetic and pharmacodynamic studies to provide valuable information for the safe and effective use of drugs in neonates, infants, and children. The meeting ultimately broadened to include discussion about other subgroups. The main conclusions of the meeting were:

  1. 1.

    The population approach, pharmacokinetic and pharmacodynamic analysis, is a valuable tool both for drug registration purposes and for optimal dosing of drugs in specific groups of patients

  2. 2.

    Population pharmacokinetic and pharmacodynamic studies are able to ‘fill in the gaps’ in registration of drugs, for example, to provide information on optimal pediatric dosing. Such studies provide a basis for enhancing product information to improve rational prescribing

  3. 3.

    Expertise is required to perform the population studies and expertise, with a clinical perspective, is also required to evaluate such studies if they are to be submitted as part of a drug registration dossier. Such expertise is available in the Australasian region and is increasing. Centers of excellence with the appropriate expertise to advise and assist should be encouraged to develop and grow in the region

  4. 4.

    The use of the population approach by the pharmaceutical industry needs to be encour-aged to provide valuable information not obtainable by other techniques. The acceptance of population pharmacokinetic and pharmacodynamic analyses by regulatory agencies also needs to be encouraged, and

  5. 5.

    Development of the population approach to pharmacokinetics and pharmacodynamics is needed from a public health perspective to ensure that all available information is collected and used to improve the way drugs are used. This important endeavor needs funding and support at the local and international levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aarons L. Population pharmacokinetics: Theory and practice. Br J Clin Pharmacol. 1991;32:669–670.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: Theory and clinical application. Clin Pharmacokinet. 1985;11:387–401.

    Article  Google Scholar 

  3. Sheiner LB, Grasela TH. An introduction to mixed effect modelling: concepts, definitions and justification. J Pharmacokinet Biopharm. 1991;Suppl:11S–23S.

    Google Scholar 

  4. Holford NHG, Peck CC. Population pharmacodynamic and drug development. In: van Boxtel CJ, Holford NHG, Danhof M, Eds. The in vivo study of drug action. London: Elsevier Science;1992.

    Google Scholar 

  5. Vozeh S, Steimer J-L, Rowland M, Morselli P, Mentre F, Balant LP, Aarons L. The use of population pharmacokinetics in drug development. Clin Pharmacokinet. 1996;30:81–93.

    Article  CAS  PubMed  Google Scholar 

  6. Steimer J-L, Ebelin M-E, Van Bree J. Pharmacokinetic and pharmacodynamic data and models in clinical trials. Eur J Drug Metab Pharmacokinet. 1993;18:61–76.

    Article  CAS  PubMed  Google Scholar 

  7. Aarons L. Sparse data analysis. Eur J Drug Metab Pharmacokinet. 1993;18:97–100.

    Article  CAS  PubMed  Google Scholar 

  8. Kearns GL. Drug development for infants and children: Rescuing the therapeutic orphan. Drug Info J. 1996;30:1121–1123.

    Article  Google Scholar 

  9. Shirkey H. Editorial comment: Therapeutic orphans. J Pediatr. 1968;72:119–120.

    Article  CAS  PubMed  Google Scholar 

  10. Cote CJ, Kauffman RE, Troendle GJ, Lambert GH. Is the “therapeutic orphan” about to be adopted? Pediatr. 1996;98:118–123.

    CAS  Google Scholar 

  11. Australian Drug Evaluation Committee. Report of the working party on the registration of drugs for use in children. October 1997.

  12. Kauffman RE, Kearns GL. Pharmacokinetics studies in pediatric patients: Clinical and ethical considerations. Clin Pharmacokinet. 1992;23:10–29.

    Article  CAS  PubMed  Google Scholar 

  13. Reed MD. The ontogeny of drug disposition: Focus on drug absorption, distribution, and excretion. Drug Info J. 1996;30:1129–1134.

    Article  Google Scholar 

  14. Leeder JS. Developmental aspects of drug metabolism in children. Drug Info J. 1996;30:1135–1143.

    Article  Google Scholar 

  15. Roberts R, Maldonado S. FDA center for drug evaluation and research (CDER) pediatric plan and new regulations. Drug Info J. 1996;30:1125–1127.

    Article  Google Scholar 

  16. FDA Center for Drug Evaluation and Research. Guidance for industry: Population pharmacokinetics. Draft Guidance, September 1997.

    Google Scholar 

  17. Wilson JT, Kearns GL, Murphy D, Yaffe SJ. Pediatric labelling requirements: Implications for pharmacokinetic studies. Clin Pharmacokinet. 1994;26: 308–325.

    Article  CAS  PubMed  Google Scholar 

  18. Wade JR. Population pharmacokinetics and pharmacodynamics: European regulatory experiences. In: Balant LP, Aarons L, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;48–53.

    Google Scholar 

  19. Ette EI, Miller R, Gillespie WR, et al. The population approach: FDA experience. In: Aarons L, et al,Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in die Field of Scientific and Technical Research; 1997;271–275.

    Google Scholar 

  20. CPMP/ICH/378/95 Dose-response information to support drug registration.

  21. CPMP/ICH/379/95 Studies in support of special population: Geriatrics.

  22. CPMP/EWP/560/95 Note for guidance on the Investigation of Drug Interactions.

  23. Ludden TM. Evaluation of potential drug-drug interactions using the population approach. In: Aarons L, et al., Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997; 39–46.

    Google Scholar 

  24. CPMP/EWP/462/95 Note for Guidance on Clinical Investigation of Medicinal Products in Children.

  25. CPMP/ICH/289/95 (Step 3) Note for guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data.

  26. Aarons L, Balant LP, Mentre F, Morselli P, Rowland M, Steimer JL, Vozeh S. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol. 1996;49:251–254.

    Article  CAS  PubMed  Google Scholar 

  27. Grasela TH, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther. 1985;8:374–383.

    Article  PubMed  Google Scholar 

  28. Tanigawara Y. Recent applications of population pharmacokinetic approach: Pre-marketing and postmarketing. Aarons L et al, Eds. The Population Approach: Measuring and Managing Variability in Re-sponse, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;25–28.

    Google Scholar 

  29. Aarons L, Balant LP, Mentré F, Morselli P, Rowland M, Steimer JL, Vozeh S. Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol. 1994;46: 389–391.

    Article  CAS  PubMed  Google Scholar 

  30. Collart L, Balschke TF, Boucher F, Prober CG. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther. 1992;18:71–80.

    Article  CAS  PubMed  Google Scholar 

  31. Hale MD, Gillespie WR, Gupta SK, Holford NHG. Clinical trial simulation: Streamlining your drug development process. Appl Clin Trials. 1996;5:35–40.

    Google Scholar 

  32. del Mar Fernandez de Gatta M, Garcia MJ, Lanao JM, Dominguez-Gil A. Bayesian forecasting in pae-diatric populations. Clin Pharmacokinet. 1996;31: 325–330.

    Article  Google Scholar 

  33. Lee TC, Charles BG, Steer P, Flenady V, Shearman A. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther. 1997;61:628–640.

    Article  CAS  PubMed  Google Scholar 

  34. McLachlan AJ, Tett SE. Pharmacokinetics of fluconazole in people with HIV infection: A population analysis. Br J Clin Pharmacol. 1996;41:291–298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tett S, Moore S, Ray J. Pharmacokinetics and bio-availability of fluconazole in two groups of males with HIV infection compared with a group of males without HIV infection. Antimicrob Agents Chemother. 1995;39:1835–1841.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Holford NHG, Peace K. The effect of tacrine and lecithin in Alzheimer’s disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol. 1994;47:17–24.

    CAS  PubMed  Google Scholar 

  37. Holford NHG, Peace K. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992;89:11471–11475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Holford NHG. Population models for Alzheimer’s and Parkinson’s disease. In: Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;93–104.

    Google Scholar 

  39. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther. 1998;11:173–179.

    Google Scholar 

  40. Delgado Iribarnegaray MF, Santo Bueldga D, Garcia Sanchez MJ, Otero MJ, Falcao AC, Dominguez-Gil A. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit. 1997;19:132–139.

    Article  CAS  PubMed  Google Scholar 

  41. Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit. 1996;18:245–253.

    Article  CAS  PubMed  Google Scholar 

  42. Wiest DB, Pinson JB, Gal PS, Brundage RC, Schall S, Ransom JL, Weaver RL, Purohit D, Brown Y. Population pharmacokinetics of intravenous indo-methacin in neonates with symptomatic patent ductus arteriosus. Clin Pharmacol Ther. 1991;49:550–557.

    Article  CAS  PubMed  Google Scholar 

  43. Burtin P, Jacqz-Aigrain E, Girard P, Lenclen R, Magny JF, Betremieux P, Tehiry C, Desplanques L, Mussat P. Clin Pharmacol Ther. 1994;56:615–625.

    Article  CAS  PubMed  Google Scholar 

  44. Thomson AH, Tucker GT. Gerontokinetics—a reappraisal. Br J Clin Pharmacol. 1992;33:1–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Thomson AH, Kelly JG, Whiting B. Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. Br J Clin Pharmacol. 1989;27:57–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Thomson AH, Rosario M, Murray LS, Elliot HL. Marimastat in healthy volunteers and patients with cancer. In: Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;287.

    Google Scholar 

  47. Theis JGW, Koren G. Maternal and fetal clinical pharmacology. In Speight TM, Holford NHG, Eds. Avery’s Drug Treatment. 4th Edition. Auckland: ADIS International; 1997;76–126.

    Google Scholar 

  48. Vanhove GF, Gries JM, Verorta D, Sheiner LB, Coombs R, Collier AC, Blaschke TF. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41:2433–2438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Tucker GT, Rostami-Hodjegan A. Metabolic variability in populations. In Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997;9–13.

    Google Scholar 

  50. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisal. Br J Clin Pharmacol. 1997;44:219–225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Holford NHG. The target concentration approach to clinical drug development. Clin Pharmacokinet. 1995;29:287–291.

    Article  CAS  PubMed  Google Scholar 

  52. Reigner BG, Williams PEO, Patel IH, Steimer JL, Peck C, van Brummelen P. An evaluation of the integration of pharmacokinetic and pharmacody-namic principles in clinical drug development. Clin Pharmacokinet. 1997;33:142–152.

    Article  CAS  PubMed  Google Scholar 

  53. Mentré F, Ebelin ME. Validation of population pharmacokinetic/pharmacodynamic analyses; Review of proposed approaches. In Aarons L, et al, Eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997; 147–160.

    Google Scholar 

  54. Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. J Pharmacokinet Biopharm. 1992;20: 279–294.

    Article  CAS  PubMed  Google Scholar 

  55. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503–512.

    Article  CAS  PubMed  Google Scholar 

  56. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486–495.

    Article  CAS  PubMed  Google Scholar 

  57. Ette EI, Ludden TM. Population pharmacokinetic modelling: The importance of informative graphics. Pharm Res. 1995;12:1845–1855.

    Article  CAS  PubMed  Google Scholar 

  58. Kearns GL, Weber W, Harnisch L, Darville T, Blumer JL, Powell K, Wells TG, Jacobs RF. Single dose pharmacokinetics of cefpirome in paediatric patients. Clin Drug Invest. 1995;10:71–85.

    Article  CAS  Google Scholar 

  59. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm. 1994;22:165–177.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, University of Queensland, Brisbane, Australia

    Susan E. Tett PHD, BPHARM(HONS)

  2. Department of Pharmacology & Clinical Pharmacology, University of Auckland, New Zealand

    Nicholas H. G. Holford MSC, MBCHB, FRACP

  3. Department of Pharmacy, University of Sydney, Australia

    Andrew J. McLachlan PHD, BPHARM(HONS)

Authors
  1. Susan E. Tett PHD, BPHARM(HONS)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas H. G. Holford MSC, MBCHB, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew J. McLachlan PHD, BPHARM(HONS)
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tett, S.E., Holford, N.H.G. & McLachlan, A.J. Population Pharmacokinetics and Pharmacodynamics: An Underutilized Resource. Ther Innov Regul Sci 32, 693–710 (1998). https://doi.org/10.1177/009286159803200310

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/009286159803200310

Key Words

Search

Navigation